VOLUME 3 , ISSUE 1 ( January-June, 2013 ) > List of Articles
Salimur Rahman, Mamun Al-Mahtab, Faroque Ahmed, Md Fazal Karim, Md Dalil Uddin
Citation Information : Rahman S, Al-Mahtab M, Ahmed F, Fazal Karim M, Dalil Uddin M. Ribavirin as a Therapeutic Modality in Patients with Severe Acute Hepatitis E. Euroasian J Hepatogastroenterol 2013; 3 (1):39-41.
DOI: 10.5005/jp-journals-10018-1060
License: CC BY-NC 4.0
Published Online: 01-01-2013
Copyright Statement: Copyright © 2013; The Author(s).
Background: With the postulation that ribavirin, an antiviral agent, can modulate the clinical course of severe acute hepatitis due to hepatitis E virus (HEV), a clinical trial was conducted in patients with acute hepatitis E. Materials and methods: A total of 24 patients with severe acute hepatitis E were enrolled in this study. Ribavirin was given at a dose of 400 mg, twice a day for 28 days. The clinical course of the disease was assessed on a regular basis. Results: Out of 24 patients in this cohort, three patients were lost during follow-up and their prognosis remains unknown. A total of six patients died during follow-up. The rest 15 patients showed improvement of their pathological conditions during observation period. Conclusion: Although preliminary, this study indicates that more information is required about beneficial and detrimental effects of ribavirin in patients with severe acute hepatitis E. This study inspired optimism that a randomized-controlled trial of ribavirin should be adopted in severe acute hepatitis E to develop proper in sights in this regard.
© Jaypee Brothers Medical Publishers (P) LTD.
We use cookies on this site to enhance your user experience.
By clicking any link on this page you are giving your consent for us to set cookies.